Loading...
Market
Which major pharmaceutical company will first commercialize anti-IL-11 therapy by end of 2025?
2
Resolution / Starting Odds
Pfizer • 25%
Merck • 25%
Johnson & Johnson • 25%
Other • 25%
Official announcements from pharmaceutical companies and press releases
Story
Study Shows Anti-IL-11 Therapy Extends Male Mouse Lifespan by 22.5%, Female by 25%
Jul 17, 2024, 04:20 PM
A recent study published in Nature has found that inhibiting the pro-inflammatory cytokine interleukin-11 (IL-11) can extend the lifespan of mice by up to 25%. The research demonstrated that both genetic deletion and an anti-IL-11 drug were effective in increasing the lifespans of laboratory mice. The treated mice exhibited fewer age-related health problems and maintained a more youthful appearance, earning them the nickname 'supermodel grannies' in the lab. The median lifespan of male mice increased by 22.5% and female mice by 25%. These findings are significant as anti-IL-11 therapies are already undergoing human clinical trials, raising hopes for potential applications in slowing human ageing.
View original story
Similar markets
Pfizer • 25%
Moderna • 25%
Roche • 25%
Other • 25%
Yes • 50%
No • 50%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Approved • 25%
Yes • 50%
No • 50%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by another regulatory body • 25%
Not approved by any major regulatory body • 25%
Nature • 25%
The Lancet • 25%
JAMA • 25%
Other • 25%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Yes • 50%
No • 50%
Pfizer • 25%
Merck • 25%
GlaxoSmithKline • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%